Fate Therapeutics, Inc. (FATE)

Oncology Corporate Profile

Stock Performance

1.9300
-0.0100

HQ Location

3535 General Atomics Court, Ste 200
San Diego, CA 92121

Company Description

Fate Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including certain hematologic malignancies, lysosomal storage disorders and muscular dystrophies. The Company utilizes established pharmacologic modalities, including small molecules and therapeutic proteins, and well-characterized biological mechanisms to enhance the therapeutic potential of adult stem cells.

Website: http://www.fatetherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
prohemastem cell therapeuticVarious cancer typesII

View additional information on product candidates here »

Pipeline image

Source


http://www.fatetherapeutics.com

Recent News Headlines

Fate Therapeutics Reports Fourth Quarter 2016 Financial Results

3/16/2017 08:00 pm

[GlobeNewswire] - First Subject Treated with ProTmune™ for GvHD Prevention. IND Cleared by FDA for FATE-NK100 Natural Killer Cell Product Candidate in AML. First-of-Kind Cancer Immunotherapy Derived from Engineered Pluripotent ...

Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy

3/13/2017 12:00 pm

[GlobeNewswire] - SAN DIEGO, March 13, 2017-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2016 Financial Results

3/9/2017 09:00 pm

[GlobeNewswire] - SAN DIEGO, March 09, 2017-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...

Explosive Stocks Under $10

3/7/2017 07:04 pm

Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting

3/2/2017 09:00 pm

[GlobeNewswire] - SAN DIEGO, March 02, 2017-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced ...

Fate Therapeutics to Present at Two Upcoming Conferences in March

3/1/2017 09:00 pm

[GlobeNewswire] - SAN DIEGO, March 01, 2017-- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today ...

Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy

2/27/2017 01:00 pm

[GlobeNewswire] - Off-the-Shelf Natural Killer Cell Therapy Being Developed to Complement Standard-of-Care Monoclonal Antibody Treatment for Cancer. First-of-Kind Product Candidate to be Manufactured from an Engineered ...

Fate Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference

2/8/2017 09:00 pm

[GlobeNewswire] - SAN DIEGO, Feb. 08, 2017-- Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that ...

Fate Therapeutics Announces First Patient Treated in ProTmune™ PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease

1/5/2017 01:01 pm

[at noodls] - SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune ...

Fate Therapeutics Announces First Patient Treated in ProTmune™ PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease

1/5/2017 01:00 pm

[GlobeNewswire] - SAN DIEGO, Jan. 05, 2017-- Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that ...